shares of roivant sciences ltd roiv surged in the extended session thursday following a report that roche holding rog was close to buying an experimental drug from the biotech company roivant shares surged 10 after hours following a 16 gain during the regular trading day to close at 1160 late thursday the wall street journal reported that roivant was close to cutting a deal to sell its treatment candidate for ulcerative colitis and crohn’s disease drug for more than 7 billion citing unnamed sources close to the matter that happens to be in the neighborhood of roivant’s market cap which was 89 billion at thursday’s close according to factset data the journal said the deal could be announced “in the coming days” in december roivant and pfizer inc pfe formed a subsidiary rvt3101 to commercialize the drug pfizer owns a 25 stake of the subsidiary